• Prescribing Information
  • Patient Information
  • Patient Site
  • Medical Information
  • CE & BZA
    CE & BZA
    Efficacy & Safety
    DUAVEE® Logo
    DUAVEE® Logo

    Samples and Savings Card

    Announcement Title

    Please be advised that DUAVEE is currently out of stock. For medical questions on DUAVEE and for supply updates, please contact Pfizer Medical Information at 1‑800‑438‑1985.

    Start your appropriate patients on DUAVEE® (conjugated estrogens/bazedoxifene) tablets with samples

    Check sample eligibility

    Eligible DUAVEE patients may pay as little as $25.* Savings up to $70 per prescription. Up to 12 uses per calendar year

    No membership fees.

    Order Savings Cards

    *Terms and Conditions

    By using this Pay As Little As $25 Savings Card (coupon), you acknowledge that you currently meet the eligibility criteria and will comply with the Terms and Conditions described below:

    • Patients are not eligible to use this coupon if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
    • Patients must have private insurance. Offer is not valid for cash-paying patients. You must pay the first $25 of your out-of-pocket expense per prescription filled. The value of this coupon is limited to $70 per use or the amount of your co-pay, whichever is less. There is a maximum savings of $840 per calendar year. For example, if your original out-of-pocket expense is $95, you will pay $25 out-of-pocket and save $70 with this offer.
    • This coupon is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
    • You must deduct the value of this coupon from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. 
    • You are responsible for reporting use of this coupon to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the coupon, as may be required. You should not use the coupon if your insurer or health plan prohibits use of manufacturer coupons.
    • You must be 18 years of age or older to redeem the coupon.
    • This coupon is not valid where prohibited by law.
    • Coupon cannot be combined with any other savings, free trial or similar offer for the specified prescription.
    • Coupon will be accepted only at participating pharmacies.
    • This coupon is not health insurance.
    • Offer good only in the U.S. and Puerto Rico.
    • Coupon is limited to 1 per person during this offering period and is not transferable.
    • A coupon may not be redeemed more than once per month up to a maximum of 12 times per calendar year.
    • No other purchase is necessary.
    • Data related to your redemption of the coupon may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other coupon redemptions and will not identify you.
    • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
    • Offer expires 12/31/2021.

    If your pharmacy does not accept this offer or if you use a mail-order service:

    • Pay for your DUAVEE prescription as you normally would.
    • Send a copy of original pharmacy receipt (cash register receipt not valid) with product name, date, and amount paid circled to:

      DUAVEE Savings Program
      2250 Perimeter Park Drive, Suite 300
      Morrisville, NC 27560
    Be sure to include a copy of the DUAVEE Savings Card, your name, and your mailing address.
    ​​​​​​​
    For more information, call 1-866-881-2545, write Pfizer, Attn: DUAVEE, 235 East 42nd Street, New York, NY 10017, or visit www.DUAVEE.com.

    INDICATIONS

    DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus:

    • Treatment of moderate to severe vasomotor symptoms associated with menopause
    • Prevention of postmenopausal osteoporosis

    Limitation of Use: DUAVEE should be used for the shortest duration consistent with treatment goals and risks for the individual woman.

    Women taking DUAVEE® (conjugated estrogens/bazedoxifene) should not be taking progestins, additional estrogens, or additional estrogen agonist/antagonists.

    There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. DUAVEE contains bazedoxifene, an estrogen agonist/antagonist, to reduce the risk of endometrial hyperplasia that can occur with estrogens, and which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling, when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

    Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia.

    The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT). Should any of these occur or be suspected, DUAVEE should be discontinued immediately.

    The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older.

    DUAVEE should not be used in women with undiagnosed abnormal uterine bleeding; known, suspected, or past history of breast cancer or estrogen-dependent neoplasia; active or past history of venous or arterial thromboembolism; hypersensitivity to estrogens, bazedoxifene, or any ingredients; known hepatic impairment or disease; known thrombophilic disorders. Women who are pregnant should not use DUAVEE.

    Estrogen agonist/antagonists, including bazedoxifene, and estrogens individually are known to increase the risk of VTE.

    The use of estrogen-alone has been reported to result in an increase in abnormal mammograms requiring further evaluation. The effect of treatment with DUAVEE on the risk of breast and ovarian cancer is unknown.

    Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.

    Adverse reactions more common in the DUAVEE treatment group in four placebo-controlled studies were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.

    DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus:

    • Treatment of moderate to severe vasomotor symptoms associated with menopause
    • Prevention of postmenopausal osteoporosis

    Limitation of Use: DUAVEE should be used for the shortest duration consistent with treatment goals and risks for the individual woman.

    Please see Full Prescribing Information, including BOXED WARNING and Patient Information.